Genmab — Oktober 2025

[gentogen]

Hvis nogen skulle være i tvivl, så er salget steget i både US og resten af verden (med en lille milliard...)

[E_L]

Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics https://ir.merus.nl/news-releases/news-release-details/merus-announces-publication-abstract-petosemtamab-metastatic

[Solsen]

Safety look good

[E_L]

in Dutch, by KBC - Merus: veelbelovende eerste klinische data voor petosemtamab bij darmkanker https://www.bolero.be/nl/analyse-en-inzicht/blog/merus-veelbelovende-eerste-klinische-data-voor-petosemtamab-bij-darmkanker?utm_source=rss

[Pensionisten]

Hvad skete der lige med kursen på Genmab. Synes ikke at have set nyheder, der kan foranledige så brat et fald?

[Vitus]

Neeej - der er stadigvæk stærke kræfter, der holder øje med Genmab. Mon ikke det er det !

[bikube]

Det var tydeligt USA, der trykkede de ned, men nu stiger den lige så hurtigt igen. Jeg kan ikke se noget nyt i USA heller.

[gdn55]

Enig Vitus

[E_L]

fallbacks so far are very benign... if we could range / stabilise a bit here around this 2100 level and make a nice base for the next rise EL would be very happy

[E_L]

Targeted Therapy Offers Hope for Metastatic Cervical Cancer https://blog.dana-farber.org/insight/2025/10/targeted-therapy-offers-hope-cervical-cancer/

[bikube]

Thanks for the story E L, it´s nearly unbelievale, but fantastic.

[E_L]

Petosemtamab shows first colorectal promise https://www.oncologypipeline.com/apexonco/petosemtamab-shows-first-colorectal-promise

[E_L]

teclistamab - Myeloma Drug Performs Well in Autoimmune Diseases https://www.medpagetoday.com/rheumatology/generalrheumatology/117966

[E_L]

TECVAYLI plus DARZALEX FASPRO combination regimen significantly
improves progression-free survival and overall survival versus standard of care https://www.jnj.com/media-center/press-releases/tecvayli-plus-darzalex-faspro-combination-regimen-significantly-improves-progression-free-survival-and-overall-survival-versus-standard-of-care

[E_L]

• At almost three years follow-up, the combination of TECVAYLI and DARZALEX FASPRO met the primary endpoint of progression-free survival (PFS) - Independent Data Monitoring Committee (IDMC) recommended unblinding the study based on statistically significant results

[E_L]

J&J claims a Tecvayli/Darzalex combo win https://www.oncologypipeline.com/apexonco/jj-claims-tecvaylidarzalex-combo-win

[ProinvestorNEWS]

Genmab-partner viser bedre overlevelsesmuligheder for kræftsyge i kombinationsstudie https://proinvestor.com/investornyt/1371488/genmab-partner-viser-bedre-overlevelsesmuligheder-for-kraeftsyge-i-kombinationsstudie

[bikube]

Måske derfor de ikke ville købe "Superdara".

[Elmer]

Her en vurdering med hjælp fra copilot med info fra Proinvestor. Hvis Tecvayli/Darzalex bliver en ny SOC i relapsede/refraktære myelom-patienter, kan royalty-strømmen blive en vigtig vækstdriver for Genmab – især hvis Darzalex fortsætter sin blockbuster-status og Tecvayli bliver en fast del af regimet.

[JKY_VH]

Aktiespararna ger köpråd för Genmab. "Aktien har stigit en del under hösten men med höjda prognoser och ett
lovande förvärv ser vi fortsatt potential. Rådet blir köp med riktkurs 2.500 danska kronor", skriver Aktiespararna.